Armata Pharmaceuticals Total Assets 2006-2021 | ARMP

Armata Pharmaceuticals total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Armata Pharmaceuticals Annual Total Assets
(Millions of US $)
2020 $40
2019 $25
2018 $15
2017 $11
2016 $18
2015 $31
2014 $29
2013 $41
2012 $19
2009 $5
2008 $7
2007 $28
2006 $17
2005 $49
Armata Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2021-09-30 $43
2021-06-30 $48
2021-03-31 $53
2020-12-31 $40
2020-09-30 $46
2020-06-30 $49
2020-03-31 $44
2019-12-31 $25
2019-09-30 $29
2019-06-30 $35
2019-03-31 $10
2018-12-31 $15
2018-09-30 $11
2018-06-30 $12
2018-03-31 $14
2017-12-31 $11
2017-09-30 $14
2017-06-30 $15
2017-03-31 $14
2016-12-31 $18
2016-09-30 $26
2016-06-30 $29
2016-03-31 $28
2015-12-31 $31
2015-09-30 $34
2015-06-30 $36
2015-03-31 $39
2014-12-31 $29
2014-09-30 $28
2014-06-30 $31
2014-03-31 $34
2013-12-31 $41
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $19
2009-12-31 $5
2009-09-30 $5
2009-06-30 $4
2009-03-31 $5
2008-12-31 $7
2008-09-30 $19
2008-06-30 $23
2008-03-31 $24
2007-12-31 $28
2007-09-30 $32
2007-06-30 $37
2007-03-31 $22
2006-12-31 $17
2006-09-30 $20
2006-06-30 $23
2006-03-31 $51
2005-12-31 $49
2005-09-30 $52
2005-06-30 $60
2005-03-31 $65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.137B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.639B 8.76
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $10.895B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $7.620B 0.00
Emergent Biosolutions (EBS) United States $2.497B 8.98
Arcus Biosciences (RCUS) United States $2.167B 0.00
Myovant Sciences (MYOV) United Kingdom $1.222B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.110B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.206B 0.00
Ambrx Biopharma (AMAM) United States $0.195B 0.00
Enzo Biochem (ENZ) United States $0.157B 20.19